• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

    2/2/23 10:38:01 AM ET
    $IMCC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $IMCC alert in real time by email
    SC 13G/A 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 01)*
     
    IM CANNABIS CORP. 

    (Name of Issuer)
     
    Common Shares, no par value

    (Title of Class of Securities)
     
    44969Q307

    (CUSIP Number)
     
    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         o  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         x  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  44969Q307      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     GABAY RAFAEL RIFAT
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   o
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Israel
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     870,268
       
    6 SHARED VOTING POWER
      
     154
       
    7 SOLE DISPOSITIVE POWER
      
     870,268
       
    8 SHARED DISPOSITIVE POWER
      
     154
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     870,422
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     11.4990%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IN
     

    FOOTNOTES
      
     
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    IM CANNABIS CORP.

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    Kibbutz Glil Yam
    Central District
    Israel 4690500

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    GABAY RAFAEL RIFAT

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    Haetrog 83
    Moshave Ganot
    Israel 5029300

     
    (c)
    Citizenship
     
     
    Israel

     
    (d)
    Title of Class of Securities
     
     
    Common Shares, no par value

     
    (e)
    CUSIP Number
     
     
    44969Q307

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 870,422

     
    (b)
    Percent of class: 11.4990%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 870,268

     
    (ii)
    Shared power to vote or to direct the vote: 154

     
    (iii)
    Sole power to dispose or to direct the disposition of: 870,268

     
    (iv)
    Shared power to dispose or to direct the disposition of: 154

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
    N/A
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    N/A
     
    Item 8.
    Identification and Classification of Members of the Group
     
    N/A
     
    Item 9.
    Notice of Dissolution of Group
     
    N/A
     
     
     

     
     
     
    Item 10.
    Certification
      
    Not applicable.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      
        
    Date: January 31, 2022
    By:
    /s/  Rafael Rifat Gabay 
       Name: Rafael Rifat Gabay 
       Title:  Individual 
        
     
    Footnotes:

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $IMCC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMCC

    DatePrice TargetRatingAnalyst
    10/5/2021$8.00Buy
    ROTH Capital
    7/14/2021Buy
    Desjardins
    7/14/2021$10.50Buy
    Desjardins
    More analyst ratings

    $IMCC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IM Cannabis Announces Filing of Information Circular for Upcoming Annual General and Special Meeting and Provides Additional Information on the Focus Transaction

      TORONTO and GLIL YAM, Israel, May 7, 2025 /PRNewswire/ -- IM Cannabis Corp. (NASDAQ:IMCC) (CSE:IMCC) (the "Company" or "IM Cannabis"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that, further its news release dated April 11, 2025 (the "April 11 Release"), it has filed a management information circular (the "Circular") in connection with the upcoming annual general and special meeting of the shareholders of the Company ("Shareholders") to be held on May 23, 2025 (the "Meeting"). Capitalized terms not otherwise defined herein have the meanings attributed to them in the April 11 Release.     Meeting Details The Company's board of directors

      5/7/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

      TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens.     The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the

      5/6/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Provides Corporate Updates

      TORONTO and GLIL YAM, Israel, April 11, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IM Cannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, today announced the following corporate updates.     Nasdaq Notification Letter The Company has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") dated April 9, 2025, notifying the Company that it is no longer in compliance with Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) (the "Listing Rule") requires companies listed on the Nasdaq Capital Market to maintain a minimum of US$2.5 million in stockholders'

      4/11/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Leadership Updates

    Live Leadership Updates

    See more
    • IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

      TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ --  IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC) (CSE:IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company's board of directors (the "Board") effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company's commitment to driving growth while focusing on sustainable profitability. "We are thrilled to welcome Shmulik to our Board of Directors," said Oren Shuster, Chief Executive Officer of

      9/11/24 8:30:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Announces the appointment of Uri Birenberg as Chief Financial Officer

      TORONTO and GLIL YAM, Israel, Oct. 10, 2023 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Uri Birenberg will join the company's leadership team as Chief Financial Officer effective October 10, 2023.  This appointment strengthens IMC's financial leadership and strategic direction for achieving sustainable profitability. "We're delighted to welcome Uri as our new Chief Financial Officer at IMC. His impressive track record and extensive experience with large scale international organizations, as well as with startups, make him an outstandin

      10/10/23 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Corp. Appoints Rinat Efrima as New Chief Executive Officer of IMC Holdings, the Company's Israeli Subsidiary

      Oren Shuster remains Chief Executive Officer and Director of IM Cannabis Corp.; other managerial changes include the promotion of Yael Harrosh to Chief Legal and Operations Officer of IM Cannabis Corp.TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / January 13, 2022 / IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE:IMCC)(NASDAQ:IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany today announced the appointment of Rinat Efrima as the new Chief Executive Officer of IMC Holdings Ltd. ("IMC Holdings"), the Company's wholly-owned Israeli subsidiary. Ms. Efrima will join the Company in the first quarter of 2022. In addition, Ya

      1/13/22 8:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH Capital initiated coverage on IM Cannabis with a new price target

      ROTH Capital initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $8.00

      10/5/21 7:57:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Desjardins initiated coverage on IMC Mortgage Co

      Desjardins initiated coverage of IMC Mortgage Co with a rating of Buy

      7/14/21 8:40:32 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • Desjardins initiated coverage on IM Cannabis with a new price target

      Desjardins initiated coverage of IM Cannabis with a rating of Buy and set a new price target of $10.50

      7/14/21 7:01:53 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by IM Cannabis Corp.

      SC 13G - IM Cannabis Corp. (0001792030) (Subject)

      2/21/23 10:56:41 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by IM Cannabis Corp. (Amendment)

      SC 13D/A - IM Cannabis Corp. (0001792030) (Subject)

      2/8/23 1:29:15 PM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by IM Cannabis Corp. (Amendment)

      SC 13G/A - IM Cannabis Corp. (0001792030) (Subject)

      2/2/23 10:38:01 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    Financials

    Live finance-specific insights

    See more
    • IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th at 9:00am ET

      TORONTO and GLIL YAM, Israel, May 6, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the first quarter 2025 ended March 31, 2025, on Thursday, May 15, 2025, before the market opens.     The Company will host a zoom web conference on the same day at 9:00am ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the

      5/6/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis Reports Fourth Quarter and Full Year 2024 Financial Results

      Q4 2024 Caps a Year of Strategic and Operational Improvements for IMC with 25% Revenue Growth, 42% decrease in Operating Expenses, and $0.5M Adjusted EBITDA Profit TORONTO and GLIL YAM, Israel, March 31, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ:IMCC) (CSE:IMCC), an international medical cannabis company, is pleased to announce its financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all amounts are reported in Canadian dollars and are compared to the quarter ended December 31, 2023. The Company's audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2023 and accompanying manage

      3/31/25 8:39:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • IM Cannabis to Report Fourth Quarter and Full Year 2024 Financial Results on Monday, March 31 2025 at 9:00am ET

      TORONTO and GLIL YAM, Israel, March 20, 2025 /PRNewswire/ -- IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company," "IMCannabis," or "IMC"), a leading medical cannabis company with operations in Israel and Germany, will report operational and financial results for the fourth quarter and full year 2024 ended December 31, 2024, on Monday, March 31, 2025 before the market opens. The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration. If you are unable to join us live, a

      3/20/25 7:00:00 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care

    $IMCC
    SEC Filings

    See more
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/7/25 7:17:55 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/6/25 7:28:10 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by IM Cannabis Corp.

      6-K - IM Cannabis Corp. (0001792030) (Filer)

      5/5/25 7:19:52 AM ET
      $IMCC
      Medicinal Chemicals and Botanical Products
      Health Care